Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
Iniparib (BSI-201)
Cat No.
CEI-0328
Description
As a competitive ATP inhibitor, BSI-201(iniparib) is one of the most specific and effective C-nitroso-derivative PARP1 inhibitor.
Alias
SAR240550
CAS No.
160003-66-7
Molecular Weight
292.03
Purity
>99%
Storage
2 years at -20centigrade Powder
Synonyms
SAR240550
Targets
PARP
Molecular Formula
C7H5IN2O3
Chemical Name
4-iodo-3-nitrobenzamide
Solubility
DMSO 58 mg/mL Water
In vitro
As a competitive ATP inhibitor, BSI-201(iniparib) is one of the most specific and effective C-nitroso-derivative PARP1 inhibitor. In breast and ovarian carcinomas that harbor BRCA2 mutations, BSI-201(iniparib) shows inhibition to those cell lines. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells, and the primary mechanism of action for iniparib is likely not via inhibition of PARP activity.
In vivo
Patients received paclitaxel 175 mg/m(2) IV over 3h followed by carboplatin area under the curve (AUC)=six over 30 min on day one of 21 day cycles plus iniparib 4 mg/kg IV over 1h twice weekly beginning on day one. Iniparib plus paclitaxel and carboplatin did not show significant activity.
Download
Download Datasheet